Table 10.

Prevalence rates of MetS according AHA/NHLB definition by new antipsychotic treatment, at baseline and after 3 months, (New-AP, CMD-set, N = 476)

Visit 1 (Baseline)
Cohort	N	n	%	95% CI
New-Olz	206	79	38.4	31.7 to 45.4
New-Risp	69	24	34.8	23.7 to 47.2
New-Quet	33	18	54.6	36.4 to 71.9
New-Atyp	72	34	47.2	35.3 to 59.4
New-Typ	16	12	75.0	47.6 to 92.7
New-Comb	80	44	55.0	43.5 to 66.2
CMD-total	476	211	44.3	39.8 to 48.9
Visit 2 (month-3)
Cohort	N	n	%	95% CI
New-Olz	206	93	45.2	38.2 to 52.2
New-Risp	69	34	49.3	37.0 to 61.6
New-Quet	33	16	48.5	30.8 to 66.5
New-Atyp	72	34	47.2	35.3 to 59.4
New-Typ	16	11	68.8	41.3 to 89.0
New-Comb	80	48	60.0	48.4 to 70.8
CMD-total	476	236	49.6	45.0 to 54.2

Abbreviations: AHA/NHLB = American Heart Association/National Heart, Lung and Blood Institute

CI = confidence interval, CMD = complete metabolic data; MetS = metabolic syndrome; NCEP-ATP III = National Cholesterol Education Program, Adult Treatment Panel 3rd report; New-AP = new antipsychotic treatment